AU2017211540B2 - Combination of an OX40 agonist and a 4-1BB agonist monoclonal antibody for treating cancer - Google Patents

Combination of an OX40 agonist and a 4-1BB agonist monoclonal antibody for treating cancer Download PDF

Info

Publication number
AU2017211540B2
AU2017211540B2 AU2017211540A AU2017211540A AU2017211540B2 AU 2017211540 B2 AU2017211540 B2 AU 2017211540B2 AU 2017211540 A AU2017211540 A AU 2017211540A AU 2017211540 A AU2017211540 A AU 2017211540A AU 2017211540 B2 AU2017211540 B2 AU 2017211540B2
Authority
AU
Australia
Prior art keywords
agonist
seq
amino acid
antibody
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017211540A
Other languages
English (en)
Other versions
AU2017211540A1 (en
Inventor
Hua Long
Aron David THALL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU2017211540A1 publication Critical patent/AU2017211540A1/en
Application granted granted Critical
Publication of AU2017211540B2 publication Critical patent/AU2017211540B2/en
Priority to AU2020210145A priority Critical patent/AU2020210145A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017211540A 2016-01-25 2017-01-17 Combination of an OX40 agonist and a 4-1BB agonist monoclonal antibody for treating cancer Ceased AU2017211540B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020210145A AU2020210145A1 (en) 2016-01-25 2020-07-27 Combination of an OX40 agonist and a 4-1BB agonist monoclonal antibody for treating cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662286616P 2016-01-25 2016-01-25
US62/286,616 2016-01-25
PCT/IB2017/050244 WO2017130076A1 (en) 2016-01-25 2017-01-17 Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020210145A Division AU2020210145A1 (en) 2016-01-25 2020-07-27 Combination of an OX40 agonist and a 4-1BB agonist monoclonal antibody for treating cancer

Publications (2)

Publication Number Publication Date
AU2017211540A1 AU2017211540A1 (en) 2018-07-19
AU2017211540B2 true AU2017211540B2 (en) 2020-04-30

Family

ID=57956335

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017211540A Ceased AU2017211540B2 (en) 2016-01-25 2017-01-17 Combination of an OX40 agonist and a 4-1BB agonist monoclonal antibody for treating cancer
AU2020210145A Abandoned AU2020210145A1 (en) 2016-01-25 2020-07-27 Combination of an OX40 agonist and a 4-1BB agonist monoclonal antibody for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020210145A Abandoned AU2020210145A1 (en) 2016-01-25 2020-07-27 Combination of an OX40 agonist and a 4-1BB agonist monoclonal antibody for treating cancer

Country Status (12)

Country Link
US (1) US20190031765A1 (enExample)
EP (1) EP3408294A1 (enExample)
JP (1) JP6783312B2 (enExample)
KR (2) KR20210013777A (enExample)
CN (1) CN108473587A (enExample)
AU (2) AU2017211540B2 (enExample)
BR (1) BR112018014016A2 (enExample)
CA (1) CA2955184A1 (enExample)
HK (1) HK1259253A1 (enExample)
MX (1) MX2018008995A (enExample)
RU (1) RU2748949C2 (enExample)
WO (1) WO2017130076A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc. anticorpos anti-cd137 e métodos de uso dos mesmos
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
SG10201913147WA (en) 2017-07-11 2020-02-27 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
CN111936507B (zh) * 2018-03-23 2022-11-01 苏州丁孚靶点生物技术有限公司 Ox40抗原多肽及其用途
CN110357961B (zh) * 2018-04-10 2022-08-23 无锡智康弘义生物科技有限公司 抗人4-1bb单克隆抗体及其制备方法和用途
WO2019196868A1 (en) 2018-04-10 2019-10-17 Wuxi Biologics (Shanghai) Co., Ltd. A monoclonal antibody against human 4-1bb, method for preparing the same, and use thereof
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
JP7598312B2 (ja) 2018-07-23 2024-12-11 ハイデルベルク ファーマ リサーチ ゲーエムベーハー 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
WO2020216947A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
WO2020240360A1 (en) * 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
PH12022550709A1 (en) 2019-09-25 2023-03-27 Pfizer Polyheterocyclic modulators of sting (stimulator of interferon genes)
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
MX2022008412A (es) 2020-01-07 2022-08-08 Univ Texas Variantes de enzima que agotan metiltioadenosina/adenosina mejorada humana para terapia de cancer.
KR20220132555A (ko) 2020-01-29 2022-09-30 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Nrg1 융합체를 사용한 암 치료를 위한 egfr/her2 티로신 키나제 억제제 및/또는 her2/her3 항체의 사용
KR20220133238A (ko) 2020-01-29 2022-10-04 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Nrg1 융합체가 있는 암의 치료를 위한 포지오티닙의 용도
JP2023504675A (ja) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンの処置のための結合分子
WO2022002063A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 一种4-1bb结合蛋白及其应用
CN114515335A (zh) * 2020-11-19 2022-05-20 百奥泰生物制药股份有限公司 抗ox40抗体在治疗肿瘤或癌症中的应用
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
WO2022250502A1 (en) * 2021-05-27 2022-12-01 Yuhan Corporation Ox40 agonist and use thereof
CN118684772A (zh) * 2021-09-09 2024-09-24 广东东阳光药业股份有限公司 抗4-1bb的激动型抗体及其应用
US20250084155A1 (en) 2021-09-29 2025-03-13 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009079335A1 (en) * 2007-12-14 2009-06-25 Medarex, Inc. Binding molecules to the human ox40 receptor
WO2015179236A1 (en) * 2014-05-21 2015-11-26 Pfizer Inc. Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DK1060247T3 (da) 1998-02-24 2009-01-26 Sisters Of Providence In Orego Sammensætning indeholdende et OX-40-receptorbindingsmiddel eller en nukleinsyre, der koder for det samme og fremgangsmåder til at foröge antigenspecifikt immunrespons
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
CA2588157A1 (en) 2004-11-17 2006-05-26 Board Of Regents, The University Of Texas System Cancer immunotherapy incorporating p53
US20080194596A1 (en) 2005-06-03 2008-08-14 Frizer Inc. Therapeutic Combination Including a Selective Erbb2 Inhibitor
NZ729044A (en) * 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
EP2726275B1 (en) 2011-06-30 2019-12-04 Compagnie Générale des Etablissements Michelin Method and apparatus for installing a tread ring upon a tire carcass
US9828432B2 (en) 2012-02-06 2017-11-28 Providence Health & Services—Oregon Cancer treatment and monitoring methods using OX40 agonists
MX2016007965A (es) 2013-12-17 2016-10-28 Genentech Inc Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
RU2766890C2 (ru) * 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009079335A1 (en) * 2007-12-14 2009-06-25 Medarex, Inc. Binding molecules to the human ox40 receptor
WO2015179236A1 (en) * 2014-05-21 2015-11-26 Pfizer Inc. Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ADLER, Adam J. et al., Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. ONCOIMMUNOLOGY, vol. 2, no. 1, 2013, page e22837.1- e22837.11 *
DUBROT, Juan et al., Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells. CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 59, no. 11, 2010, pages 1621-1631 *
GRAY, Juliet C. et al., Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 38, no. 9, 2008, pages 2499-2511 *
LEE, S.-J. et al., 4-lBB and OX40 Dual Costimulation Synergistically Stimulate Primary Specific CD8 T Cells for Robust Effector Function. THE JOURNAL OF IMMUNOLOGY, vol. 173, no. 5, 2004, pages 3002-3012 *
QUI, H. Z. et al., CD134 Plus CD137 Dual Costimulation Induces Eomesodermin in CD4 T Cells to Program Cytotoxic Th1 Differentiation. J. IMMUNOLOGY, vol. 187, no. 7, 2011, pages 3555-3564 *

Also Published As

Publication number Publication date
AU2020210145A1 (en) 2020-08-13
JP6783312B2 (ja) 2020-11-11
RU2018127164A3 (enExample) 2020-02-28
RU2018127164A (ru) 2020-02-28
KR20180103150A (ko) 2018-09-18
KR20210013777A (ko) 2021-02-05
CN108473587A (zh) 2018-08-31
HK1259253A1 (zh) 2019-11-29
JP2019506403A (ja) 2019-03-07
AU2017211540A1 (en) 2018-07-19
RU2748949C2 (ru) 2021-06-02
WO2017130076A1 (en) 2017-08-03
MX2018008995A (es) 2019-01-10
US20190031765A1 (en) 2019-01-31
EP3408294A1 (en) 2018-12-05
BR112018014016A2 (pt) 2019-02-05
CA2955184A1 (en) 2017-07-25

Similar Documents

Publication Publication Date Title
US12534530B2 (en) Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
AU2020210145A1 (en) Combination of an OX40 agonist and a 4-1BB agonist monoclonal antibody for treating cancer
US10899840B2 (en) Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
US10023649B2 (en) Method of treating cancer with a combination of an anti-CCR4 antibody and a 4-1BB agonist
US10869924B2 (en) PD-L1 antagonist combination treatments
JP6586087B2 (ja) Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療
US20180092901A1 (en) Combination of a pd-1 antagonist and a vegf-r/fgfr/ret tyrosine kinase inhibitor for treating cancer
US20210317214A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist for treating patients with non-microsatellite instability-high or proficient mismatch repair colorectal cancer
HK40010365A (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired